Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Munich - Delayed Quote EUR

Cynata Therapeutics Ltd (51S.MU)

Compare

0.1640

0.0000

(0.00%)

As of 8:25:58 AM GMT+1. Market Open.

Cynata Therapeutics Limited (ASX:CYP): Is Breakeven Near?

With the business potentially at an important milestone, we thought we'd take a closer look at Cynata Therapeutics...

Simply Wall St. 15 days ago

CYYNF
3 Promising ASX Penny Stocks With Market Caps Below A$200M

As the ASX200 experiences a slight downturn, with sectors like Discretionary and Financials facing challenges, Utilities and Energy have shown resilience. In such fluctuating market conditions, identifying promising investment opportunities can be crucial. Penny stocks, though an older term, still represent smaller or emerging companies that could offer substantial growth potential when supported by strong financials and clear growth strategies.

Simply Wall St. 2 months ago

CCR.AX

CYYNF

QCKSF
CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial

Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has successfully completed its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU).

PR Newswire 2 months ago

CYYNF
Cannindah Resources Leads 3 ASX Penny Stocks Worth Considering

The Australian market has seen a slight downturn, with the ASX200 down 1.1% at 8,162 points in afternoon trade, influenced by sectoral declines in Financials and Health Care. Amid these broader market movements, investors may find opportunities in penny stocks—an investment area that continues to intrigue despite its old-fashioned name. These stocks often represent smaller or newer companies that can offer significant value when they possess strong financial foundations and growth potential.

Simply Wall St. 3 months ago

CAE.AX

CYYNF

SB2.AX
Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. 7 months ago

CYYNF
Further CYP-001 GvHD Clinical Data Published in Nature Medicine

Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the publication of two-year follow-up data of CYP-001 in patients with steroid-resistant acute graft versus host disease (SR-aGvHD) in the prestigious peer-reviewed journal Nature Medicine.

PR Newswire 9 months ago

CYYNF
Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial

Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU).

PR Newswire 10 months ago

CYYNF
First Patient Treated in Phase 2 GvHD Trial

Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD).

PR Newswire 11 months ago

CYYNF

Performance Overview

Return	51S.MU	S&P/ASX 200 [XJO]
YTD	+29.13%	+0.16%
1-Year	+17.99%	+6.15%
3-Year	-48.75%	+15.16%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cynata Therapeutics Ltd (51S.MU)

Cynata Therapeutics Limited (ASX:CYP): Is Breakeven Near?

3 Promising ASX Penny Stocks With Market Caps Below A$200M

CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial

Cannindah Resources Leads 3 ASX Penny Stocks Worth Considering

Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Further CYP-001 GvHD Clinical Data Published in Nature Medicine

Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial

First Patient Treated in Phase 2 GvHD Trial

Performance Overview